trial · primary record
Tebapivat
Sickle Cell Disease
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 59 |
| Primary completion | 2027-05 |
| Primary endpoint | Percentage of Participants With Hb Response |
| Registry ID | NCT06924970 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:58.305Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06924970
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.